Literature DB >> 34806760

Common Fundamentals of Psoriasis and Depression.

Stefanie Hölsken, Frederik Krefting, Manfred Schedlowski, Wiebke Sondermann1.   

Abstract

Psoriasis is an inflammatory, immune-mediated disease that is frequently associated with psychological comorbidities such as depression. The stigma patients feel because of the appearance of their skin may contribute to the high psycho-social burden of psoriasis. However, there is emerging evidence that overlapping biological mechanisms are, to a substantial degree, responsible for the close interaction between psoriasis and depression. Increased proinflammatory mediators, such as C-reactive protein or interleukin-6, are present in both psoriasis and depression, indicating that inflammation may represent a pathophysiological link between the diseases. Anti-inflammatory biologic therapies treat the clinical manifestations of psoriasis, but might also play a significant role in reducing associated depressive symptoms in patients with psoriasis. Comparison between single studies focusing on the change in depressive symptoms in psoriasis is limited by inconsistency in the depression screening tools applied.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34806760      PMCID: PMC9455336          DOI: 10.2340/actadv.v101.565

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  97 in total

1.  DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis.

Authors:  D Mermin; L Boursault; B Milpied; A Taieb; K Ezzedine; J Seneschal
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-29       Impact factor: 6.166

2.  The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study.

Authors:  Joyce Leman; Shernaz Walton; Alison M Layton; Kathleen A Ward; Sandy McBride; Sandeep Cliff; Anthony Downs; Margarita Landeira; Anthony Bewley
Journal:  J Dermatolog Treat       Date:  2019-05-01       Impact factor: 3.359

3.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors:  Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

4.  Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

Authors:  Richard G Langley; Steven R Feldman; Chenglong Han; Brad Schenkel; Philippe Szapary; Ming-Chun Hsu; Jean-Paul Ortonne; Kenneth B Gordon; Alexa B Kimball
Journal:  J Am Acad Dermatol       Date:  2010-05-11       Impact factor: 11.527

Review 5.  The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis.

Authors:  Emmilia A Dowlatshahi; Marlies Wakkee; Lidia R Arends; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2013-11-27       Impact factor: 8.551

6.  Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.

Authors:  Kristian Reich; April W Armstrong; Peter Foley; Michael Song; Megan Miller; Y K Shen; Yin You; Chenglong Han; Kenneth B Gordon
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

Review 7.  Recommendations for detection of individual risk for comorbidities in patients with psoriasis.

Authors:  Johannes Wohlrab; Gabriele Fiedler; Sascha Gerdes; Alexander Nast; Sandra Philipp; Marc A Radtke; Diamant Thaçi; Wolfgang Koenig; Andreas F H Pfeiffer; Martin Härter; Michael P Schön
Journal:  Arch Dermatol Res       Date:  2013-02-03       Impact factor: 3.017

Review 8.  Epidemiology of mental health comorbidity in psoriasis.

Authors:  J J Wu; S R Feldman; J Koo; L B Marangell
Journal:  J Dermatolog Treat       Date:  2017-11-10       Impact factor: 3.359

Review 9.  Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: Relevance for symptoms of anxiety and depression.

Authors:  Julie Lasselin; Manfred Schedlowski; Bianka Karshikoff; Harald Engler; Mats Lekander; Jan Pieter Konsman
Journal:  Neurosci Biobehav Rev       Date:  2020-05-17       Impact factor: 8.989

Review 10.  The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Authors:  Camille Roubille; Vincent Richer; Tara Starnino; Collette McCourt; Alexandra McFarlane; Patrick Fleming; Stephanie Siu; John Kraft; Charles Lynde; Janet Pope; Wayne Gulliver; Stephanie Keeling; Jan Dutz; Louis Bessette; Robert Bissonnette; Boulos Haraoui
Journal:  Ann Rheum Dis       Date:  2015-01-05       Impact factor: 19.103

View more
  1 in total

1.  A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment.

Authors:  Qianying Yu; Xiaopei Ge; Mingyi Jing; Xiongfei Mi; Jing Guo; Min Xiao; Qing Lei; Mingling Chen
Journal:  J Immunol Res       Date:  2022-08-18       Impact factor: 4.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.